|Fluoxetine||Selective serotonin reuptake inhibitor|
|Trade names||Symbyax, Cinol Forte, Cinol Plus, Depten-OZ, M-Olan Plus, Oladay-F, Olanex-F, Olapin Forte, Olapin Plus, Olorest-F|
|ATC code||N06CA03 (WHO)|
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a single capsule containing the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.
Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine and fluoxetine. Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating.
Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.
In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.
Like other SSRIs, olanzapine/fluoxetine carries a boxed warning stating that it could increase the risk of suicidal thoughts and behaviors in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.
- "Symbyax Prescribing Information" (PDF). Eli Lilly and Company. 2010.
- Grohol, J. "FDA Approves Symbyax for Treatment Resistant Depression". Psych Central Blog.
- McIntyre R, Katzman M (2003). "The role of atypical antipsychotics in bipolar depression and anxiety disorders.". Bipolar Disord. 5 Suppl 2: 20–35. doi:10.1111/j.1399-2406.2003.00061.x. PMID 14700010.
- Pederson KJ, Roerig JL, Mitchell JE (2003). "Towards the pharmacotherapy of eating disorders". Expert Opin Pharmacother. 4 (10): 1659–78. doi:10.1517/14656522.214.171.1249. PMID 14521477.
- Koran LM, Ringold AL, Elliott MA (2000). "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder". J Clin Psychiatry. 61 (7): 514–7. doi:10.4088/JCP.v61n0709. PMID 10937610.
- Stein MB, Kline NA, Matloff JL (2003). "Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study". Am J Psychiatry. 159 (10): 1777–9. doi:10.1176/appi.ajp.159.10.1777. PMID 12359687.
- Drugs.com http://www.drugs.com/pdr/symbyax.html